The LWCN Strategy Board maintains strategic oversight of Lymphoedema Wales Clinical Network (LWCN) and considers, scrutinises and agrees recommendations made by the LWCN Programme Board providing assurance and endorsement to the All Wales NHS Chief Executives Forum. The LWCN Strategy Board provides the source of composite advice to Welsh Government, Chief Executive Officers and Health Boards as required and informs Welsh Government of the progress towards benefit realisation of the programme. The Board meets bi-annually and is chaired by a Chief Executive of one of the seven Welsh Health Boards.
The current chair of the LWCN Strategy Board is Nicola Prygodzicz, Chief Executive, Aneurin Bevan University Health Board and includes the following representation:
Clinical Director, LWCN
National Lymphoedema Education & Research Lead, LWCN
Programme Management Office Representation, LWCN
Chair LWCN Programme Board
Health of Older People’s Health & Chronic Conditions Management, Welsh Government
Director of Therapies and Health Sciences, SBUHB
Director of Improvement & Innovation, CTMUHB
Director Clinical Strategy, PTHB
Director of Transformation, BCUHB
Director of Nursing, CVUHB
Director Primary and Community Care, ABUHB
Associate Medical Director Transformation and Value Based Health Care, HDUHB
Chief Pharmacy, Velindre
Deputy Director of Finance, Velindre
Director of Digital Strategy, Digital Health and Care Wales
Academic Representative
Health Care Inspectorate Wales Representative
Patient Representatives
Assistant Director Finance, Finance Delivery Unit